Efzofitimod Phase 3 Study Completes Last Patient Visit
aTyr Pharma completed the final patient visit in its Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis, anticipating...
Arch Biopartners Initiates Phase 2 Pontiak Trial
Arch Biopartners has initiated patient recruitment for its Phase II PONTIAK trial in Alberta, Canada. This trial will assess...
CytoMed Therapeutics Achieves Angelica Trial Milestone
CytoMed Therapeutics, a Singapore-based biopharmaceutical company, announced the successful completion of dose level 1 in its first-in-human Phase I...
Connect Biopharma to End ADR Program, List Directly on Nasdaq
Connect Biopharma Holdings Limited plans to terminate its American Depositary Share (ADS) program and list its ordinary shares directly...
Urteste S.A. to Launch Panuri Test Clinical Study Q3 2025
Urteste S.A. has completed development of its Panuri test for pancreatic cancer and plans to begin clinical trials in...
Optima II Trial Shows Long-Term Durability of Zusduri in Bladder Cancer
A five-year long-term extension study of the Phase 2b OPTIMA II trial, published in Clinical Genitourinary Cancer, demonstrated durable...
Arrivent’s Pivotal Phase 3 Furvent Data for Firmonertinib Projected Early 2026
ArriVent BioPharma anticipates topline data from its global Phase 3 FURVENT trial in early 2026. The trial is evaluating...
nkgen’s FDA Authorization for Neurodegenerative Disease Treatment
NKGen Biotech has received FDA authorization for an Expanded Access Program (EAP) to explore the use of its cryopreserved,...
Oruka Therapeutics Gets IND Clearance for ORKA-001 Psoriasis Trial
Oruka Therapeutics received FDA clearance for its Investigational New Drug (IND) application to begin the Phase 2a clinical trial,...
Recordati Cuts Document Lifecycle Time by 25% Through Centralized Oversight on Veeva
At the 2025 Veeva R&D and Quality Summit, Luca Manfro, R&D Digital Solutions Manager at Recordati, shared how the...